Yusuf Hameed/LinkedIn
May 23, 2026, 16:44
Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
Yusuf Hameed, Anesthesiologist, Principal of Angel Investor, shared a post on X:
“Promising news for hemophilia A patients:
Many patients in Sangamo Therapeutics‘ giroctocogene fitelparvovec trials maintain strong benefits (fewer bleeds, lower treatment burden) through approximately 3-4 years of follow-up—a real advance vs lifelong prophylaxis.
Long-term (5-10+ years) data is still maturing, with individual results varying.
Big upside:
One-time gene therapy could yield major lifetime cost savings vs $300K–$800K+/yr prophylaxis (often more than $20M lifetime). Screening plus monitoring key.”
Stay updated with Hemostasis Today.
-
Oct 8, 2026, 14:10Rebecca Akpeloo: PE as an Overlooked Threat in Sickle Cell Disease
-
Oct 8, 2026, 14:05Christina Pohlman: World Thrombosis Day – Raising Awareness of DVT
-
Oct 8, 2026, 13:59Patience Nkabe Odey: What Drives Rhesus D Screening Uptake Among Pregnant Women?
-
Oct 8, 2026, 13:50Todd Rice: ECMO at the Intersection of Anticoagulation and Respiratory Failure
-
Oct 8, 2026, 13:35Manuel Monreal: Why IVC Filter Retrieval Matters for VTE Outcomes
-
Oct 8, 2026, 12:53Hellen Ishikawa-Ankerhold: PhD and Postdoctoral Positions in Advanced Microscopy and Immunothrombosis at LMU Munich
-
Oct 8, 2026, 12:45Pedro Perez: World Thrombosis Day 2026 – Raising Awareness of Women’s VTE Risk
-
Oct 8, 2026, 12:20Berrin Gunaydin: Functional Biomarkers of Iron Deficiency in Pregnancy
-
Oct 8, 2026, 11:45Wolfgang Miesbach: Milvexian After Acute Coronary Syndrome – What LIBREXIA ACS Found